Alzheimer's and cardiovascular disease share common genetics in some patients
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers led by scientists at UC San Francisco and Washington University School of Medicine in St. Louis.
The research analyzed genome-wide data from over 1.5 million individuals, making it one of the largest-ever studies of Alzheimer's genetics. The authors hope the findings will lead to improved early diagnosis and potentially new preventative strategies for Alzheimer's disease, which currently affects 5.7 million people in the U.S. and has no cure.
Mounting clinical and epidemiological evidence has pointed to a link between heart disease and Alzheimer's disease, but a biological relationship between the two conditions has remained controversial. Many patients diagnosed with Alzheimer's disease also show signs of cardiovascular disease, and postmortem studies reveal that the brains of many Alzheimer's patients show signs of vascular disease, which some scientists speculate could drive the onset of dementia. These observations led to hopes of preventing Alzheimer's by treating cardiovascular symptoms, but initial genetic studies and failed clinical trials of cardiovascular drugs called statins in Alzheimer's disease have cast doubt on this possibility.
The new study, published November 9, 2018 in Acta Neuropathologica, shows that Alzheimer's and cardiovascular disease do share common genetics in some individuals, raising new questions about whether this shared biology could be targeted to slow down or prevent both diseases.
"These results imply that irrespective of what causes what, cardiovascular and Alzheimer's pathology co-occur because they are linked genetically. That is, if you carry this handful of gene variants you may be at risk for not only heart disease but also Alzheimer's," said UCSF neurodegeneration researcher Rahul Desikan, MD, PhD, a clinician-scientist whose lab is known for developing a so-called polygenic hazard score for Alzheimer's that predicts the age at which an individual is likely to begin experiencing symptoms of dementia based on their genetic background.
To identify genetic variants that confer risk of both cardiovascular disease and Alzheimer's disease, the researchers used statistical techniques pioneered by Desikan's lab in collaboration with Ole Andreassen, MD, PhD, at the University of Oslo, and Anders Dale, PhD, at UC San Diego, that allowed them to combine multiple large-scale genome-wide association studies (GWAS) — a type of genetic study that makes statistical links between various disease states and widely shared variations in the genetic code.
Ultimately Desikan's team was able to analyze the combined impact of such genetic markers on both cardiovascular disease risk — based on five GWAS studies of more than one million individuals — and on Alzheimer's risk — based on three GWAS studies of nearly 30,000 Alzheimer's patients and more than 50,000 age-matched controls.
"Our approach works by combining and leveraging these massive GWAS studies to make discoveries that would otherwise be invisible," Desikan said. "We are essentially borrowing statistical power."
This analysis enabled the researchers to identify 90 spots in the genome where specific DNA variants increased patients' combined chance of developing both Alzheimer's disease and heightened blood levels of lipid molecules, including HDL and LDL cholesterol and triglycerides, which are common risk factors for cardiovascular disease.
The researchers confirmed that six of these 90 regions had very strong "genome-wide significant" effects on Alzheimer's and heightened blood lipid levels, including several within genes that had never before been linked to dementia risk. These included several sites within the CELF1/MTCH2/SPI1 region on chromosome 11, which had previously been linked to immune system biology.
In contrast, though patients diagnosed with Alzheimer's also often exhibit other cardiovascular risk factors, such as unhealthy levels of belly fat, type 2 diabetes, and chest pain or other symptoms of coronary artery disease, the authors could find no clear overlapping genetics between Alzheimer's disease and these risk factors.
"These results suggest that Alzheimer's and cardiovascular disease could both be influenced by genetic defects that impair the body's ability to processes lipids properly," said study first author Iris Broce-Diaz, PhD, a postdoctoral researcher in Desikan's lab. "But they also suggest that the link between Alzheimer's and other cardiovascular risk factors are not likely due to common genetics, though they could be linked by diet or other lifestyle factors."
"This is exciting because we know that levels of cholesterol and other lipids in the blood are highly modifiable through changes in diet or with drugs," Broce added. "This raises the possibility that we might be able to help delay or even prevent the onset of Alzheimer's in these patients, though we'll need more data before we can say that for sure."
Desikan's team then examined whether currently healthy individuals with a family history of Alzheimer's disease were more likely to carry these newfound genetic variants, a relatively new method for studying early Alzheimer's risk factors called "Alzheimer's-by-proxy." Taking advantage of a large British research cohort called UK Biobank, the researchers found these variants were much more likely to be present in the genomes of 50,000 individuals who had one or more parents diagnosed with Alzheimer's disease than in nearly 330,000 individuals without a family history of the disease.
"It's remarkable that among these healthy adults with a family history of Alzheimer's, a subset of cardiovascular risk genes themselves appear to strongly influence risk of eventually developing Alzheimer's," Desikan said. "This is exactly the population we should study to see if reducing cardiovascular disease risk through lifestyle or medication can delay or prevent the onset of dementia later in life."
The researchers further confirmed their findings in a collaboration with Celeste M. Karch, PhD, an Alzheimer's expert at Washington University School of Medicine in St. Louis and co-corresponding author on the new study. Karch's team showed that the novel genes most closely tied to Alzheimer's/cardiovascular risk in the new study were differently expressed in the brains of Alzheimer's patients compared to control brains.
"This study emphasizes that we should be thinking about Alzheimer's disease holistically," Karch said. "There's a lot to learn about how the genes that are driving Alzheimer's disease risk also are driving changes throughout the body."
"This is also an exciting opportunity because we already know a great deal about these cardiovascular traits and how to target them," she added.
Desikan and Broce-Diaz are now integrating these findings into the lab's previously developed polygenic risk score, which will allow clinicians to calculate, based on a patient's genome, their combined risk for cardiovascular disease and Alzheimer's. The researchers hope that their work will help launch a precision medicine approach to testing whether controlling blood lipid levels in individuals with the newly discovered risk factors, either through diet or using established drugs such as statins, might delay or prevent the onset of Alzheimer's disease.
"That's really the goal," said Broce-Diaz. "If we can identify the subset of individuals whose cardiovascular and brain health is linked genetically, we think there's a possibility that reducing their blood lipid levels could help reduce their risk of developing dementia later in life. Such treatments haven't worked in clinical trials before, but this could be because we haven't had a good way of selecting who is most likely to benefit based on their genetics."
Authors: The study's senior authors were Rahul Desikan, MD, PhD, an assistant professor in the UCSF Department of Radiology and Biomedical Imaging, and Celeste Karch, PhD, an assistant professor of psychiatry at of Washington University School of Medicine in St. Louis. The study's co-lead authors were Iris Broce-Diaz, PhD, a postdoctoral researcher in the Desikan lab at UCSF, and Chin Hong Tan, PhD, a former Desikan lab post-doc now at Nanyang Technological University in Singapore. Desikan, Karch, and Broce-Diaz are all corresponding authors on the study. Please see the published study online for a full list of additional authors.
Funding: This work was supported by grants from the National Institutes of Health (NIH-AG046374, K01AG049152), a National Alzheimer's Coordinating Center Junior Investigator Award (RSD), RSNA Resident/Fellow Award (RSD), Foundation ASNR Alzheimer's Imaging Grant (RSD), the Research Council of Norway (#213837, #225989, #223273, #237250/EU JPND), the South East Norway Health Authority (2013-123), Norwegian Health Association and the KG Jebsen Foundation.
Disclosures: Co-author James B. Brewer, MD, PhD, of UC San Diego, served on advisory boards for Elan, Bristol-Myers Squibb, Avanir, Novartis, Genentech, and Eli Lilly, and holds stock options in CorTechs Labs, Inc. and Human Longevity, Inc. Co-author Anders M. Dale, also of UC San Diego, is a founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc., and receives research funding from General Electric Healthcare. The terms of these arrangements have been reviewed and approved by UCSD in accordance with its conflict of interest policies.
About UCSF: UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals – UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland – as well as Langley Porter Psychiatric Hospital and Clinics, UCSF Benioff Children's Physicians and the UCSF Faculty Practice. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. UCSF faculty also provide all physician care at the public Zuckerberg San Francisco General Hospital and Trauma Center, and the SF VA Medical Center. The UCSF Fresno Medical Education Program is a major branch of the University of California, San Francisco's School of Medicine. Please visit http://www.ucsf.edu/news.
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf